Lars Molinder

Active Investor

Investment Banking at Carnegie Investment Bank

Stockholm, Stockholm County

Lars Molinder, Investment Banking at Carnegie Investment Bank is an active investor based in Stockholm, Stockholm County. This profile covers what Lars Molinder backs, at which stage, and how founders can reach out in 2026.

Mr. Lars Molinder is an Angel Investor at Lars Molinder. He serves as Investment Banking at Carnegie Investment Bank. He serves as a Board member at Oblique Therapeutics. He served as Board Member at Ondek. He has over 15 years of financial sector experience working solely with companies in the healthcare sector. Lars has been the Head of Medicine and Biotechnology at the Swedish Industrial Development Fund and made over 40 investments in early stage companies ranging from medical technology and diagnostics to pharmaceuticals and biotechnology. Prior to joining Carnegie Investment Bank, Lars was the Nordic Head of Healthcare Sector and European co-Head of Healthcare Banking at Alfred Berg and ABN AMRO. Selected recent deals include: defence adviser to Gambro (PTP) and Biacore (PTP), and sole lead manager for the initial public offering of Clavis Pharma, Orexo and Biovitrum. Lars has a M.Sc. in Engineering.

Investor type: AngelVCPEInvestment Bank
Stages: Early Stage Venture
Invests in: Healthcare & BiotechSaaS & EnterpriseDeveloper Tools & DataPropTech & Real EstateMedia & Content
Location: Stockholm, Stockholm County
Typical check: $500K
Past investments: 3

Notable investments

ManoMotionABN AMROIndustrifonden

How to reach Lars Molinder

Angels and operators like Lars Molinder reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.

Frequently Asked Questions

What does Lars Molinder invest in?

Lars Molinder invests in Healthcare & Biotech, SaaS & Enterprise, Developer Tools & Data and PropTech & Real Estate, typically at Early Stage Venture. Match your sector and stage, then reach out with a personalized pitch.